This comprehensive update explores the recent advancements in the treatment landscape
of myeloid leukemia. Myeloid leukemia, a heterogeneous group of hematological …

Myeloid leukemias, although a heterogeneous group of hematopoietic stem cell neoplasms,
are arguably among the most suited for active specific immunotherapy. Nevertheless …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

However, immunotherapy, especially cellular immunotherapy, is an emerging field and on-
going research will have to address several issues to improve safety and efficacy of this …

Both acute myeloid leukemia and chronic myeloid leukemia are thought to arise from a
subpopulation of primitive cells, termed leukemic stem cells that share properties with …

The treatment landscape in MDS and AML is rapidly changing; with a goal of improving the
quality and duration of responses, a number of immune based therapies are under …

With the development of chemotherapy and hematopoietic stem cell transplantation (HSCT),
the prognosis of leukemia patients has been improved greatly in the past few decades …

Myeloid malignancies have always been at the forefront of an improved understanding of
the molecular pathogenesis of cancer. In accordance, over the last years, basic research …

Acute myeloid leukemia (AML) is a prevalent hematological malignancy that exhibits a wide
array of molecular abnormalities. Although traditional treatment modalities such as …

The European Hematology Association Theme of the year 2017–2018 has rather chosen
itself. Any other topic risked being swamped by the flood of excitement emanating from the …